INDP SEC-arkivering - Indaptus Therapeutics, Inc.- Årsrapport, fuldmagtserklæring, prospekt

Grundlæggende statistik

CIK

1857044

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Indaptus Therapeutics, Inc.

SEC Filings (Chronological Order)

Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.

May 15, 2026	EX-99.1	Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (May 15, 2026) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic corporate update. Junyi Dai, Indaptus Therapeut
May 15, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus T
May 15, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 15, 2026 INDAPTUS THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 15, 2026 INDAPTUS THERAPEUTICS, INC.
April 24, 2026	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
April 23, 2026	EX-10.1	FORM OF INDEPENDENT DIRECTOR AGREEMENT Exhibit 10.1 FORM OF INDEPENDENT DIRECTOR AGREEMENT This INDEPENDENT DIRECTOR AGREEMENT is dated (the “Agreement”) by and between INDAPTUS THERAPEUTICS, INC, a Delaware corporation (the “Company”) and [], an individual (the “Director”). WHEREAS, the Company intends to appoint the Director effective as of [] (the “Effective Date”) and desires to enter into an agreement with the Director with respec
April 23, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 INDAPTUS THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 INDAPTUS THERAPEUTICS, INC.
April 23, 2026	EX-10.2	FORM OF INDEMNIFICATION AGREEMENT Exhibit 10.2 FORM OF INDEMNIFICATION AGREEMENT THIS AGREEMENT (the “Agreement”) is made and entered into as of this day of between Indaptus Therapeutics, Inc., a Delaware corporation (“the Company”, which term shall include where appropriate any Enterprise (as hereafter defined) controlled directly or indirectly by the Company and any successor to the Company), and [] (“Indemnitee”). WITNESSETH TH
April 3, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 INDAPTUS THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 INDAPTUS THERAPEUTICS, INC.
March 24, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2026 INDAPTUS THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2026 INDAPTUS THERAPEUTICS, INC.
March 17, 2026	EX-3.7	EX-3.7 Exhibit 3.7
March 17, 2026	EX-3.6	EX-3.6 Exhibit 3.6
March 17, 2026	EX-4.1	DESCRIPTION OF SECURITIES Exhibit 4.1 DESCRIPTION OF SECURITIES General The following description of our capital stock is a summary. This summary is subject to the DGCL and the complete text of our Amended and Restated Certificate of Incorporation, as amended (“COI”), and Amended and Restated Bylaws. In this description, references to “we,” “us,” “our,” “our company” and “Indaptus” refer to Indaptus Therapeutics, Inc. and
March 17, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40652 INDAPTUS THERAP
February 27, 2026	EX-3.1	CERTIFICATE OF AMENDMENT AMENDED AND RESTATED CERTIFICATE OF INCORPORATION INDAPTUS THERAPEUTICS, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INDAPTUS THERAPEUTICS, INC. Indaptus Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”) hereby certifies as follows: A. The name of the Corporation is Indaptus Therapeutics, Inc. The Corporation was originally incorporated under the name of
February 27, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 INDAPTUS THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 INDAPTUS THERAPEUTICS, INC.
February 12, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2026 INDAPTUS THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2026 INDAPTUS THERAPEUTICS, INC.
February 12, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
February 12, 2026	EX-10.2	IRREVOCABLE PROXY AND VOTING AGREEMENT Exhibit 10.2 IRREVOCABLE PROXY AND VOTING AGREEMENT THIS IRREVOCABLE PROXY AND VOTING AGREEMENT (this “Agreement”) is being signed on February , 2026 (the “Signature Date”) by and among (a) Indaptus Therapeutics, Inc., a Delaware corporation whose shares of the Company’s common stock, par value $0.01 per share (“Common Stock”) are listed for trading on the Nasdaq Capital Market (the “Company”), (b
February 12, 2026	EX-10.1	INDAPTUS THERAPEUTICS, INC. Exhibit 10.1 INDAPTUS THERAPEUTICS, INC. February [], 2026 To: [Name of Holder] Re: Repricing of Warrants Dear Holder: Reference is made to those certain warrants to purchase shares of common stock, $0.01 par value per share (the “Common Stock”) issued to you (“Holder”, “you” or similar terminology) by Indaptus Therapeutics, Inc. (the “Company”) as set forth in Exhibit A hereto (the “Warrants”). T
January 21, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
January 20, 2026	EX-10.2	SALARY ADJUSTMENT AGREEMENT Exhibit 10.2 SALARY ADJUSTMENT AGREEMENT Effective January 15, 2026, Indaptus Therapeutics, Inc. (“Company”) and Michael J. Newman (“Officer”) hereby mutually agree that Officer’s annual salary is adjusted for the remainder of the calendar year to sixty thousand United States Dollars ($60,000 USD) per annum paid in accordance with Company’s standard payroll practice less applicable deductions. Mic
January 20, 2026	EX-10.1	SALARY ADJUSTMENT AGREEMENT Exhibit 10.1 SALARY ADJUSTMENT AGREEMENT Effective January 15, 2026, Indaptus Therapeutics, Inc. (“Company”) and Jeffrey A. Meckler (“Officer”) hereby mutually agree that Officer’s annual salary is adjusted for the remainder of the calendar year to sixty thousand United States Dollars ($60,000 USD) per annum paid in accordance with Company’s standard payroll practice less applicable deductions. Je
January 20, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 20, 2026 Date of Report (Date of earliest event reported) INDAPTUS THERAPEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 20, 2026 Date of Report (Date of earliest event reported) INDAPTUS THERAPEUTICS, INC.
January 8, 2026	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
January 8, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 8, 2026 Date of Report (Date of earliest event reported) INDAPTUS THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 8, 2026 Date of Report (Date of earliest event reported) INDAPTUS THERAPEUTICS, INC.
January 2, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 29, 2025 INDAPTUS THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 29, 2025 INDAPTUS THERAPEUTICS, INC.
December 23, 2025	EX-10.5	MUTUAL EMPLOYMENT AGREEMENT MODIFICATION Exhibit 10.5 MUTUAL EMPLOYMENT AGREEMENT MODIFICATION This Mutual Employment Agreement Modification (the “Amendment”) is entered into on this 22nd day of December, 2025 by and between Indaptus Therapeutics, Inc. (the “Company”) and Walt Linscott, Esq., Chief Operating Officer of the Company (“Officer”), collectively known herein as the “Parties.” WHEREAS, Officer and Company originally entered int
December 23, 2025	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 22, 2025 (the “Effective Date”), by and between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), and Mr. David Lazar, an Israeli and E.U. citizen residing in Panama (the “Purchaser” or “Lazar”). WHEREAS, the Company has been exploring the strategic options av
December 23, 2025	EX-3.2	CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES AAA CONVERTIBLE NON-REDEEMABLE PREFERRED STOCK INDAPTUS THERAPEUTICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) Exhibit 3.2 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES AAA CONVERTIBLE NON-REDEEMABLE PREFERRED STOCK OF INDAPTUS THERAPEUTICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) INDAPTUS THERAPEUTICS, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does he
December 23, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 22, 2025 INDAPTUS THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 22, 2025 INDAPTUS THERAPEUTICS, INC.
December 23, 2025	EX-10.3	MUTUAL EMPLOYMENT AGREEMENT MODIFICATION Exhibit 10.3 MUTUAL EMPLOYMENT AGREEMENT MODIFICATION This Mutual Employment Agreement Modification (the “Amendment”) is entered into on this 22nd day of December, 2025 by and between Indaptus Therapeutics, Inc. (the “Company”) and Michael J. Newman, Ph.D. Chief Science Officer of the Company (“Officer”), collectively known herein as the “Parties.” WHEREAS, Officer and Company originally entered i
December 23, 2025	EX-10.4	MUTUAL EMPLOYMENT AGREEMENT MODIFICATION Exhibit 10.4 MUTUAL EMPLOYMENT AGREEMENT MODIFICATION This Mutual Employment Agreement Modification (the “Amendment”) is entered into on this 22nd day of December, 2025 by and between Indaptus Therapeutics, Inc. (the “Company”) and Nir Sassi, Chief Financial Officer of the Company (“Officer”), collectively known herein as the “Parties.” WHEREAS, Officer and Company originally entered into an Emplo
December 23, 2025	EX-10.2	MUTUAL EMPLOYMENT AGREEMENT MODIFICATION Exhibit 10.2 MUTUAL EMPLOYMENT AGREEMENT MODIFICATION This Mutual Employment Agreement Modification (the “Amendment”) is entered into on this 22nd day of December, 2025 by and between Indaptus Therapeutics, Inc. (the “Company”) and Jeffrey Meckler, Chief Executive Officer of the Company (“Officer”), collectively known herein as the “Parties.” WHEREAS, Officer and Company originally entered into an
December 23, 2025	EX-3.1	CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES AA CONVERTIBLE NON-REDEEMABLE PREFERRED STOCK INDAPTUS THERAPEUTICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES AA CONVERTIBLE NON-REDEEMABLE PREFERRED STOCK OF INDAPTUS THERAPEUTICS, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) INDAPTUS THERAPEUTICS, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does her
December 23, 2025	EX-10.6	SEPARATION AGREEMENT Exhibit 10.6 SEPARATION AGREEMENT THIS AGREEMENT dated as of December 22, 2025 (“Agreement”) is made by and between Indaptus Therapeutics, Inc. (the “Company”) and Roger J. Waltzman, M.D. (“Executive”). WHEREAS, Executive is employed as the Chief Medical Officer of the Company according to that certain Employment Agreement dated as of August 7, 2023 (the “Employment Agreement”). WHEREAS, the Execu
December 23, 2025	EX-10.7	VOTING AGREEMENT Exhibit 10.7 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is being signed on December , 2025 (the “Signature Date”) by and among (a) Indaptus Therapeutics, Inc., a Delaware corporation whose Common Stock is listed for trading on the Nasdaq (the “Proxy” or the “Company”), (b) Mr. David Elliot Lazar, an individual (“Lazar”), and (c) , an individual (the “Stockholder”). WHEREAS, the Comp
November 12, 2025	EX-99.1	Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update NEW YORK (November 12, 2025) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the third quarter ended September
November 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indapt
November 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2025 INDAPTUS THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2025 INDAPTUS THERAPEUTICS, INC.
September 4, 2025	EX-99.1	Indaptus Therapeutics Provides Clinical Update Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with eac Exhibit 99.1 Indaptus Therapeutics Provides Clinical Update Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW YORK (September 4, 2025) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotech
September 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 4, 2025 INDAPTUS THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 4, 2025 INDAPTUS THERAPEUTICS, INC.
September 3, 2025	EX-10.31	430 Park Avenue \| New York, New York 10022 \| 212.356.0500 \| www.hcwco.com Member: FINRA/SIPC Exhibit 10.31 Execution Version March 16, 2025 STRICTLY CONFIDENTIAL Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 Attn: Jeffrey A. Meckler, Chief Executive Officer Dear Mr. Meckler: This letter agreement (this “Agreement”) constitutes the agreement between Indaptus Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shal
September 3, 2025	S-1/A	As filed with the Securities and Exchange Commission on September 3, 2025. As filed with the Securities and Exchange Commission on September 3, 2025. Registration No. 333-289984 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INDAPTUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 86-3158720 (State or other jurisdiction of i
September 2, 2025	EX-4.3	PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT INDAPTUS THERAPEUTICS, INC. Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT INDAPTUS THERAPEUTICS, INC. Warrant Shares: Issue Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Stoc
September 2, 2025	EX-FILING FEES	Calculation of Filing Fee Table Form S-1 (Form Type) Indaptus Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Indaptus Therapeutics, Inc.
September 2, 2025	EX-4.1	SERIES [A] [B] COMMON STOCK PURCHASE WARRANT INDAPTUS THERAPEUTICS, INC. Exhibit 4.1 SERIES [A] [B] COMMON STOCK PURCHASE WARRANT INDAPTUS THERAPEUTICS, INC. Warrant Shares: Issue Date: , 2025 THIS SERIES [A] [B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Stockh
September 2, 2025	EX-4.2	PRE-FUNDED COMMON STOCK PURCHASE WARRANT INDAPTUS THERAPEUTICS, INC. Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT INDAPTUS THERAPEUTICS, INC. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o
September 2, 2025	S-1	As filed with the Securities and Exchange Commission on September 2, 2025. As filed with the Securities and Exchange Commission on September 2, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INDAPTUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 86-3158720 (State or other jurisdiction of incorporation or organizat
September 2, 2025	424B5	INDAPTUS THERAPEUTICS, INC. Up to $2,340,000 Shares of Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-289573 PROSPECTUS SUPPLEMENT (To Prospectus dated August 20, 2025) INDAPTUS THERAPEUTICS, INC. Up to $2,340,000 Shares of Common Stock We have entered into an at-the-market offering agreement, or the Offering Agreement, dated June 1, 2022, as amended, with H.C. Wainwright & Co., LLC, or the Sales Agent or Wainwright, as sales agent relating
September 2, 2025	EX-10.30	SECURITIES PURCHASE AGREEMENT Exhibit 10.30 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se
August 19, 2025	CORRESP	Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 August 19, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Indaptus Therapeutics, Inc. (CIK 0001857044) Registration Statement No. 333-289573 on Form S-3 (the “Registration Statement”) Ladies and Gentlemen: Indaptus Therapeutics, Inc. (the “Regis
August 19, 2025	CORRESP	Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 August 19, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Indaptus Therapeutics, Inc. (CIK 0001857044) Registration Statement No. 333-289576 on Form S-3 (the “Registration Statement”) Ladies and Gentlemen: Indaptus Therapeutics, Inc. (the “Regis
August 18, 2025	LETTER	LETTER August 18, 2025 Jeffrey Meckler Chief Executive Officer Indaptus Therapeutics, Inc.
August 18, 2025	LETTER	LETTER August 18, 2025 Jeffrey Meckler Chief Executive Officer Indaptus Therapeutics, Inc.
August 13, 2025	EX-99.1	Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update — Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical Progress — Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update — Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical Progress — NEW YORK (August 13, 2025) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative can
August 13, 2025	EX-FILING FEES	Filing Fee Exhibit Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Indaptus Therapeutics, Inc.
August 13, 2025	S-3	As filed with the Securities and Exchange Commission on August 13, 2025 As filed with the Securities and Exchange Commission on August 13, 2025 Registration No.
August 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus Th
August 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 13, 2025 INDAPTUS THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 13, 2025 INDAPTUS THERAPEUTICS, INC.
August 13, 2025	S-3	As filed with the Securities and Exchange Commission on August 13, 2025 As filed with the Securities and Exchange Commission on August 13, 2025 Registration No.
August 13, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) INDAPTUS THERAPEUTICS, INC.
August 13, 2025	EX-10.3	Form of Pre-Funded Warrant Exhibit 10.3 THIS PRE-FUNDED WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS PRE-FUNDED WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: [●], 2025 Original Issue Date (as defined in subsection 2(a)): [●], 2025 Indaptus Therapeutics, Inc. Pre-Funded Common Stock Purch
July 29, 2025	8-K	Unregistered Sales of Equity Securities, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2025 INDAPTUS THERAPEUTICS, INC.
July 16, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 14, 2025 INDAPTUS THERAPEUTICS, INC.
July 1, 2025	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2025 INDAPTUS THERAPEUTICS, INC.
July 1, 2025	EX-99.1	Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants Exhibit 99.1 Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants NEW YORK, July 1, 2025 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the additional sale of approximate
June 26, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 25, 2025 INDAPTUS THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 25, 2025 INDAPTUS THERAPEUTICS, INC.
June 26, 2025	EX-3.1	Certificate of Amendment to Amended And Restated Certificate of Incorporation of Indaptus Therapeutics, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INDAPTUS THERAPEUTICS, INC. Indaptus Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”) hereby certifies as follows: A. The name of the Corporation is Indaptus Therapeutics, Inc. The Corporation was originally incorporated under the name of
June 26, 2025	EX-99.1	Indaptus Therapeutics Announces Reverse Stock Split Exhibit 99.1 Indaptus Therapeutics Announces Reverse Stock Split NEW YORK (June 25, 2025) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Board of Directors has approved a one-for-twenty eight reverse stock split of its common stock t
June 23, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 13, 2025	EX-10.4	Form of Placement Agent Agreement, dated as of May 9, 2025, by and between Indaptus Therapeutics, Inc. and Paulson Investment Company, LLC Exhibit 10.4 May 9, 2025 STRICTLY CONFIDENTIAL Jeffrey Meckler Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 PLACEMENT AGENT AGREEMENT This Placement Agent Agreement (“Agreement”) is made by and between Indaptus Therapeutics, Inc., (the “Company”), and Paulson Investment Company, LLC, a Delaware limited liability company (the “Placement Agent”), as of the date first
June 13, 2025	EX-10.1	Form of Securities Purchase Agreement, dated as of June 12, 2025, between the Company and the investors signatory thereto Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2025, between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, the Company seeks to sell an aggrega
June 13, 2025	EX-10.3	Form of Common Warrant Exhibit 10.3 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: [●], 2025 Original Issue Date (as defined in subsection 2(a)): [●], 2025 Indaptus Therapeutics, Inc. Common Stock Purchase Warrant (Void after 5:00 p.m.
June 13, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 13, 2025	EX-99.1	Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants Exhibit 99.1 Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the sale of approximately $2.3 million in ag
June 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 12, 2025 INDAPTUS THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 12, 2025 INDAPTUS THERAPEUTICS, INC.
June 13, 2025	EX-10.2	Form of Convertible Promissory Note Exhibit 10.2 CONVERTIBLE PROMISSORY NOTE THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE
June 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 10, 2025 INDAPTUS THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 10, 2025 INDAPTUS THERAPEUTICS, INC.
May 14, 2025	EX-99.1	Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update NEW YORK (May 14, 2025) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the first quarter ended March 31, 2025,
May 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus T
May 14, 2025	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2025 INDAPTUS THERAPEUTICS, INC.
April 28, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 28, 2025	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40652 INDAPTUS THER
April 28, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 17, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 27, 2025	DRS	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INDAPTUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) As confidentially submitted to the Securities and Exchange Commission on March 27, 2025.
March 13, 2025	POS AM	As filed with the Securities and Exchange Commission on March 13, 2025 As filed with the Securities and Exchange Commission on March 13, 2025 Registration No.
March 13, 2025	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2025 INDAPTUS THERAPEUTICS, INC.
March 13, 2025	EX-99.1	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update ● Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20 ● Pharmacodynamic immune activation biomarker and pharmacokinetics profiles in initial data sets appear to meet or exceed initial expectations ● E
March 13, 2025	EX-19.1	Insider Trading Policy Exhibit 19.1 INDAPTUS THERAPEUTICS, INC. INSIDER TRADING POLICY This Insider Trading Policy (the “Policy”) sets forth the policy for directors, officers, employees, consultants and contractors of Indaptus Therapeutics, Inc. and its subsidiaries (the “Company”) with respect to transactions in the Company’s securities or securities of certain other publicly traded companies while in possession of co
March 13, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40652 INDAPTUS THERAP
February 13, 2025	CORRESP	Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 February 13, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Indaptus Therapeutics, Inc. (CIK 0001857044) Registration Statement No. 333-284863 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Indaptus Therapeutics, Inc. (the “Reg
February 12, 2025	S-1	As filed with the Securities and Exchange Commission on February 12, 2025 As filed with the Securities and Exchange Commission on February 12, 2025 Registration No.
February 12, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Registration Statement on Form S-1 (Form Type) INDAPTUS THERAPEUTICS, INC.
February 12, 2025	LETTER	LETTER February 12, 2025 Jeffrey A. Meckler Chief Executive Officer Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-1 Filed February 12, 2025 File No. 333-284863 Dear Jeffrey A. Meckler: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and
February 12, 2025	EX-10.1	Form of Standby Equity Purchase Agreement dated as of February 12, 2025 by and between the Company and YA II PN Ltd. (incorporated herein by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on February 12, 2025) Exhibit 10.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of February 12, 2025, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and INDAPTUS THERAPEUTICS, INC., a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be referred to herein
February 12, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 12, 2025 INDAPTUS THERAPEUTICS, INC.
February 11, 2025	CORRESP	Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 February 11, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Indaptus Therapeutics, Inc. (CIK 0001857044) Registration Statement No. 333-284707 on Form S-3 (the “Registration Statement”) Ladies and Gentlemen: Indaptus Therapeutics, Inc. (the “Reg
February 7, 2025	LETTER	LETTER February 7, 2025 Jeffrey Meckler Chief Executive Officer Indaptus Therapeutics, Inc.
February 5, 2025	S-3	As filed with the Securities and Exchange Commission on February 5, 2025 As filed with the Securities and Exchange Commission on February 5, 2025 Registration No.
February 5, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) INDAPTUS THERAPEUTICS, INC.
January 31, 2025	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2025 INDAPTUS THERAPEUTICS, INC.
January 14, 2025	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 12, 2025, between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond
January 14, 2025	EX-99.1	Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules Exhibit 99.1 Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules NEW YORK, January 13, 2025 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase
January 14, 2025	EX-10.4	Placement Agent Agreement, dated as of January 12, 2025, by and between Indaptus Therapeutics, Inc. and Paulson Investment Company, LLC as amended by the First Amendment to the Placement Agent Agreement, dated as of December 30, 2024 (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on January 14, 2025) Exhibit 10.4 December 12, 2024 STRICTLY CONFIDENTIAL Jeffrey Meckler Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 PLACEMENT AGENT AGREEMENT This Placement Agent Agreement (“Agreement”) is made by and between Indaptus Therapeutics, Inc., (the “Company”), and Paulson Investment Company, LLC, a Delaware limited liability company (the “Placement Agent”), as of the date
January 14, 2025	EX-10.3	Form of Placement Agent Warrant Exhibit 10.3 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: [●], 2025 Original Issue Date (as defined in subsection 2(a)): [●], 2025 Indaptus Therapeutics, Inc. Placement Agent Common Stock Purchase Warrant (Void
January 14, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2025 INDAPTUS THERAPEUTICS, INC.
January 14, 2025	EX-10.2	Form of Warrant Exhibit 10.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: [●], 2024 Original Issue Date (as defined in subsection 2(a)): [●], 2024 Indaptus Therapeutics, Inc. Common Stock Purchase Warrant (Void after 5:00 p.m.
December 30, 2024	CORRESP	Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 December 30, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Indaptus Therapeutics, Inc. (CIK 0001857044) Registration Statement No. 333-284026 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Indaptus Therapeutics, Inc. (the “Reg
December 30, 2024	LETTER	LETTER December 30, 2024 Jeffrey A. Meckler Chief Executive Officer Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-1 Filed December 23, 2024 File No. 333-284026 Dear Jeffrey A. Meckler: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and
December 23, 2024	S-1	As filed with the Securities and Exchange Commission on December 23, 2024 As filed with the Securities and Exchange Commission on December 23, 2024 Registration No.
December 23, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-1 (Form Type) INDAPTUS THERAPEUTICS, INC.
November 26, 2024	SC 13D/A	INDP / Indaptus Therapeutics, Inc. / Meckler Jeffrey A Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Indaptus Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45339J105 (CUSIP Number) Jeffrey A. Meckler c/o Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New Yo
November 22, 2024	EX-10.2	Form of Warrant (incorporated herein by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the SEC on November 22, 2024) Exhibit 10.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: [●], 2024 Original Issue Date (as defined in subsection 2(a)): [●], 2024 Indaptus Therapeutics, Inc. Common Stock Purchase Warrant (Void after 5:00 p.m.
November 22, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 22, 2024 INDAPTUS THERAPEUTICS, INC.
November 22, 2024	EX-99.1	Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement Exhibit 99.1 Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement NEW YORK, November 22, 2024 – (GLOBE NEWSWIRE) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities pur
November 22, 2024	424B5	Indaptus Therapeutics, Inc. 1,817,017 Shares of Common Stock As filed Pursuant to Rule 424(b)(5) Registration No. 333-267236 PROSPECTUS SUPPLEMENT (To Prospectus dated September 9, 2022) Indaptus Therapeutics, Inc. 1,817,017 Shares of Common Stock We are offering 1,817,017 shares of our common stock, par value $0.01 per share (“common stock”) in a registered direct offering pursuant to this prospectus supplement and the accompanying prospectus and securitie
November 22, 2024	EX-1.1	Placement Agent Agreement, dated as of October 29, 2024, by and between Indaptus Therapeutics, Inc. and Paulson Investment Company, LLC, and Amendment No. 1 to Placement Agent Agreement, dated as of November 20 2024 Exhibit 1.1 October 29, 2024 STRICTLY CONFIDENTIAL Jeffrey Meckler Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 PLACEMENT AGENT AGREEMENT This Placement Agent Agreement (“Agreement”) is made by and between Indaptus Therapeutics, Inc., (the “Company”), and Paulson Investment Company, LLC, a Delaware limited liability company (the “Placement Agent”), as of the date fi
November 22, 2024	EX-10.1	Form of Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on November 22, 2024) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 22, 2024, between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con
November 22, 2024	EX-10.3	Form of Placement Agent Warrant (incorporated herein by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K filed with the SEC on November 22, 2024) Exhibit 10.3 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: [●], 2024 Original Issue Date (as defined in subsection 2(a)): [●], 2024 Indaptus Therapeutics, Inc. Placement Agent Common Stock Purchase Warrant (Void
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indapt
November 12, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2024 INDAPTUS THERAPEUTICS, INC.
November 12, 2024	EX-99.1	Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update NEW YORK (November 12, 2024) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the third quarter ended September
October 22, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 17, 2024 INDAPTUS THERAPEUTICS, INC.
October 10, 2024	SC 13D	INDP / Indaptus Therapeutics, Inc. / Meckler Jeffrey A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Indaptus Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45339J105 (CUSIP Number) Jeffrey A. Meckler c/o Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 (646) 427-2727
September 18, 2024	CORRESP	September 18, 2024 September 18, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
September 17, 2024	LETTER	LETTER September 17, 2024 Jeffrey Meckler Chief Executive Officer Indaptus Therapeutics, Inc.
September 12, 2024	S-1	As filed with the Securities and Exchange Commission on September 12, 2024 As filed with the Securities and Exchange Commission on September 12, 2024 Registration No.
September 12, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-1 (Form Type) INDAPTUS THERAPEUTICS, INC.
August 12, 2024	EX-99.1	Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update NEW YORK (August 12, 2024) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the second quarter ended June 30, 2
August 12, 2024	EX-FILING FEES	Filing fee Table Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) INDAPTUS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Amended and Restated
August 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus Th
August 12, 2024	S-8	As filed with the Securities and Exchange Commission on August 12, 2024 As filed with the Securities and Exchange Commission on August 12, 2024 Registration No.
August 12, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2024 INDAPTUS THERAPEUTICS, INC.
August 8, 2024	EX-10.2	Form of Warrant (incorporated herein by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the SEC on August 8, 2024) Exhibit 10.2 FORM OF COMMON STOCK WARRANT THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT Warrant No. CS-[●] Number of Shares: [●] (subject to adjustment) Date of Issuance: August 8, 2024 Original Issue Date (as defined in subsection 2(a)): August 8, 2024 Indaptus Therapeutics, Inc. Common Stock
August 8, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2024 INDAPTUS THERAPEUTICS, INC.
August 8, 2024	EX-10.1	Form of Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on August 8, 2024) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 7, 2024, between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit
August 8, 2024	EX-99.1	Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement Exhibit 99.1 Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement NEW YORK, Aug. 07, 2024 – (GLOBE NEWSWIRE) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase
August 8, 2024	EX-1.1	Placement Agent Agreement, dated as of July 23, 2024, by and between Indaptus Therapeutics, Inc. and Paulson Investment Company, LLC Exhibit 1.1 July 23, 2024 STRICTLY CONFIDENTIAL Jeffrey Meckler, CEO Indaptus Therapeutics, Inc Three Columbus Circle, 15th Floor New York, NY 10019 PLACEMENT AGENT AGREEMENT This Placement Agent Agreement (“Agreement”) is made by and between Indaptus Therapeutics, Inc, (the “Company”), and Paulson Investment Company, LLC, a Delaware limited liability company (the “Placement Agent”), as of the dat
August 7, 2024	424B5	Indaptus Therapeutics, Inc. 1,643,837 Shares of Common Stock As filed Pursuant to Rule 424(b)(5) Registration No. 333-267236 PROSPECTUS SUPPLEMENT (To Prospectus dated September 9, 2022) Indaptus Therapeutics, Inc. 1,643,837 Shares of Common Stock We are offering 1,643,837 shares of our common stock, par value $0.01 per share (“common stock”) in a registered direct offering pursuant to this prospectus supplement and the accompanying prospectus and a securit
August 6, 2024	424B5	INDAPTUS THERAPEUTICS, INC. Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-267236 PROSPECTUS SUPPLEMENT (To Prospectus dated September 9, 2022 and Prospectus Supplements dated September 9, 2022 and March 27, 2023) INDAPTUS THERAPEUTICS, INC. Common Stock This prospectus supplement (the “Prospectus Supplement”) supplements the prospectus dated September 9, 2022 and the prospectus supplements dated September 9, 2022,
June 7, 2024	8-K	Submission of Matters to a Vote of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 INDAPTUS THERAPEUTICS, INC.
June 7, 2024	EX-10.1	Indaptus Therapeutics, Inc. Amended and Restated 2021 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on June 7, 2024) Exhibit 10.1 INDAPTUS THERAPEUTICS, INC. (Formerly INTEC PARENT, INC.) 2021 STOCK INCENTIVE PLAN (as amended and restated effective as of June 6, 2024) Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof. 1. PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1. Purpose. The purpose of this 2021 Stock Incentive Plan (as amended, this “Plan”) is to afford a
May 22, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 22, 2024 INDAPTUS THERAPEUTICS, INC.
May 8, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2024 INDAPTUS THERAPEUTICS, INC.
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus T
May 8, 2024	EX-99.1	Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 cl Exhibit 99.1 Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 NEW YORK (May 8, 2024) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical sta
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 25, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 25, 2024 INDAPTUS THERAPEUTICS, INC.
March 13, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40652 INDAPTUS THERAP
March 13, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 13, 2024 INDAPTUS THERAPEUTICS, INC.
March 13, 2024	EX-99.1	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update ● Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 ● Initiating Multi-Dosing for patients with solid tumors NEW YORK (March 13, 2024) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the
March 13, 2024	EX-10.8	Employment Agreement between Roger J. Waltzman and Indaptus Therapeutics, Inc., effective as of August 7, 2023 (incorporated herein by reference to Exhibit 10.8 of the Company’s Annual Report on Form 10-K filed with the SEC on March 13, 2024) Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), effective as of August 7, 2023 (the “Effective Date”), is between Indaptus Therapeutics, Inc. (the “Company”) and Roger J. Waltzman (the “Executive”). WITNESSETH WHEREAS, the Company desires to employ the Executive as its Chief Medical Officer as of the Effective Date, and the Executive desires to accept such employmen
March 13, 2024	424B5	INDAPTUS THERAPEUTICS, INC. Up to $5,244,831.06 of Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-267236 PROSPECTUS SUPPLEMENT (To Prospectus dated September 9, 2022 and Prospectus Supplements dated September 9, 2022 and March 27, 2023) INDAPTUS THERAPEUTICS, INC. Up to $5,244,831.06 of Common Stock This prospectus supplement (the “Prospectus Supplement”) supplements the prospectus dated September 9, 2022 and the prospectus supplements d
March 13, 2024	EX-97.1	Indaptus Therapeutics, Inc. Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 INDAPTUS THERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Indaptus Therapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subje
March 4, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 4, 2024 INDAPTUS THERAPEUTICS, INC.
January 23, 2024	EX-3.1	Amended and Restated Bylaws of Indaptus Therapeutics, Inc., dated as of January 22, 2024 (incorporated herein by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2024) Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF INDAPTUS THERAPEUTICS, INC. ARTICLE 1 CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of the Corporation shall be fixed in the Corporation’s Certificate of Incorporation, as the same may be amended or restated from time to time (the “Certificate of Incorporation”). 1.2 OTHER OFFICES. The Corporation’s board of directors (the “Board”) may at
January 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 22, 2024 INDAPTUS THERAPEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 22, 2024 INDAPTUS THERAPEUTICS, INC.
November 6, 2023	EX-99.1	Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update NEW YORK (November 6, 2023) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. “We continue to be encouraged by early results from our first cohort of p
November 6, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indapt
November 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2023 INDAPTUS THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2023 INDAPTUS THERAPEUTICS, INC.
November 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2023 INDAPTUS THERAPEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2023 INDAPTUS THERAPEUTICS, INC.
October 31, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 INDAPTUS THERAPEUTICS, INC.
August 17, 2023	SC 13G/A	INDP / Indaptus Therapeutics Inc / Anderson Glen R. Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Indaptus Therapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 45339J 105 (CUSIP Number) Glen R. Anderson Anderson Family Trust 101 South 200 East Suite 700 Salt Lake City, Ut
August 14, 2023	EX-99.1	Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update NEW YORK (August 14, 2023) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We have recently announced the completion of the first cohort of patients in
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus Th
August 14, 2023	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2023 INDAPTUS THERAPEUTICS, INC.
August 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2023 INDAPTUS THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2023 INDAPTUS THERAPEUTICS, INC.
May 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2023 INDAPTUS THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2023 INDAPTUS THERAPEUTICS, INC.
May 11, 2023	EX-10.1	Indaptus Therapeutics, Inc. Non-Employee Director Compensation Program (Effective April 2, 2023) (incorporated herein by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023) Exhibit 10.1 Indaptus Therapeutics, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), which shall amend and restate in its entirety the Company’s existing Directors’ Com
May 11, 2023	EX-99.1	Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Enrollment Continues for Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 Exhibit 99.1 Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Enrollment Continues for Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 NEW YORK (May 11, 2023) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the first quarter ended
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus T
May 11, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 11, 2023 INDAPTUS THERAPEUTICS, INC.
April 12, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 12, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 27, 2023	424B5	INDAPTUS THERAPEUTICS, INC. Up to $3,717,317.70 of Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-267236 PROSPECTUS SUPPLEMENT (To Prospectus and Prospectus Supplement dated September 9, 2022) INDAPTUS THERAPEUTICS, INC. Up to $3,717,317.70 of Common Stock This Prospectus Supplement supplements the prospectus and the prospectus supplement, each dated September 9, 2022 (together, the “ATM Prospectus”), relating to the offer and sale of sh
March 24, 2023	EX-FILING FEES	Filing fee Table Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) INDAPTUS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2021 Stock Incentive
March 24, 2023	S-8	As filed with the Securities and Exchange Commission on March 24, 2023 As filed with the Securities and Exchange Commission on March 24, 2023 Registration No.
March 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 22, 2023 INDAPTUS THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 22, 2023 INDAPTUS THERAPEUTICS, INC.
March 17, 2023	EX-10.2	Form of Option Award Agreement (incorporated herein by reference to Exhibit 10.2 of the Company’s Annual Report on Form 10-K filed with the SEC on March 13, 2024) Exhibit 10.2 NOTICE OF OPTION GRANT You have been granted the following options (the “Options” or “Award”) to purchase shares of Common Stock, par value US$0.01 each (the “Shares”), of Indaptus Therapeutics, Inc. (the “Company”), pursuant and subject to the terms and conditions of the Company’s 2021 Stock Incentive Plan (as may be amended from time to time, the “Plan”), and the additional terms an
March 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 17, 2023 INDAPTUS THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 17, 2023 INDAPTUS THERAPEUTICS, INC.
March 17, 2023	EX-99.1	Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 Exhibit 99.1 Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 NEW YORK (March 17, 2023) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the fourth
March 17, 2023	EX-10.1	Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan Exhibit 10.1 INDAPTUS THERAPEUTICS, INC. (Formerly INTEC PARENT, INC.) 2021 STOCK INCENTIVE PLAN (dated as of June 21, 2021) Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof. 1. PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1. Purpose. The purpose of this 2021 Stock Incentive Plan (as amended, this “Plan”) is to afford an incentive to Service Prov
March 17, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40652 INDAPTUS THERAP
February 14, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2023 INDAPTUS THERAPEUTICS, INC.
December 30, 2022	424B3	Indaptus Therapeutics, Inc. 4,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-269000 Indaptus Therapeutics, Inc. 4,000,000 Shares of Common Stock This prospectus relates to the offer and sale of up to 4,000,000 shares of our common stock, par value $0.01 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of common stock to which this p
December 30, 2022	CORRESP	Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, New York 10019 CORRESP 1 filename1.htm Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, New York 10019 December 30, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-269000 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of
December 29, 2022	LETTER	LETTER United States securities and exchange commission logo December 29, 2022 Jeffrey Meckler Chief Executive Officer Indaptus Therapeutics, Inc.
December 23, 2022	EX-10.1	Purchase Agreement, dated December 22, 2022, by and between Indaptus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 23, 2022) Exhibit 10.1 EXECUTION VERSION PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of December 22, 2022, is made by and between INDAPTUS THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes
December 23, 2022	S-1	As filed with the Securities and Exchange Commission on December 23, 2022 As filed with the Securities and Exchange Commission on December 23, 2022 Registration No.
December 23, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 22, 2022 INDAPTUS THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 22, 2022 INDAPTUS THERAPEUTICS, INC.
December 23, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Indaptus Therapeutics, Inc.
December 23, 2022	EX-10.2	Registration Rights Agreement, dated December 22, 2022, by and between Indaptus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on December 23, 2022) Exhibit 10.2 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of December 22, 2022, is entered into by and between INDAPTUS THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the ?Investor?). Capitalized terms used h
November 10, 2022	EX-99.1	Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Company Remains On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022 Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Company Remains On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022 NEW YORK (November 10, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Company?), today announces financial results for the third quarter ended September 3
November 10, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2022 INDAPTUS THERAPEUTICS, INC.
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indapt
September 30, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 29, 2022 INDAPTUS THERAPEUTICS, INC.
September 9, 2022	RW	Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 September 9, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-265350 Ladies and Gentlemen: On June 1, 2022, Indaptus Therapeutics, Inc. (the ?Company?) filed the Regist
September 7, 2022	LETTER	LETTER United States securities and exchange commission logo September 7, 2022 Nir Sassi Chief Financial Officer Indaptus Therapeutics, Inc.
September 7, 2022	CORRESP	Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, New York 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, New York 10019 September 7, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-267236 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Indap
September 1, 2022	EX-1.2	At the Market Offering Agreement, dated June 1, 2022, by and between Indaptus Therapeutics, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 1.2 of the Company’s Registration Statement on Form S-3 filed on September 1, 2022) Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT June 1, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Indaptus Therapeutics, Inc., a corporation organized under the laws of Delaware (the ?Company?), confirms its agreement (this ?Agreement?) with H.C. Wainwright & Co., LLC (the ?Manager?) as follows: 1. Definitions. The terms that follow, when used in t
September 1, 2022	EX-4.2	Form of Subordinated Indenture Exhibit 4.2 INDAPTUS THERAPEUTICS, INC. TO [], as Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY THE GUARANTORS NAMED HEREIN INDENTURE Dated as of [], 20[] SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page Article One Definitions and Other Provisions of General Application 1 Section 101 Definitions 1 Section 102 Compliance Certificates and Opinions 11 Section 103 Form of Documents Delivere
September 1, 2022	EX-FILING FEES	Filing Fee Exhibit Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Indaptus Therapeutics, Inc.
September 1, 2022	S-3	As filed with the Securities and Exchange Commission on September 1, 2022 As filed with the Securities and Exchange Commission on September 1, 2022 Registration No.
September 1, 2022	EX-1.3	Amendment Letter, dated September 1, 2022, between Indaptus Therapeutics, Inc. and H.C. Wainwright & Co. LLC to the At-the-Market Sales Agreement, dated June 1, 2022. Exhibit 1.3 September 1, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Reference is hereby made to that certain At The Market Offering Agreement dated June 1, 2022 (the “ATM Agreement”) by and between Indaptus Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”) and H.C. Wainwright & Co., LLC (the “Manager”). Capita
September 1, 2022	EX-4.1	Form of Senior Indenture Exhibit 4.1 INDAPTUS THERAPEUTICS, INC. TO [], as Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY THE GUARANTORS NAMED HEREIN INDENTURE Dated as of [], 20[] SENIOR DEBT SECURITIES TABLE OF CONTENTS Page Article One Definitions and Other Provisions of General Application 1 Section 101 Definitions 1 Section 102 Compliance Certificates and Opinions 10 Section 103 Form of Documents Delivered to T
August 8, 2022	EX-99.1	Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of De Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in 2022 NEW YORK (August 8, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Co
August 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus Th
August 8, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2022 INDAPTUS THERAPEUTICS, INC.
August 4, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
August 4, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 formdef14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
July 21, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 20, 2022 INDAPTUS THERAPEUTICS, INC.
July 21, 2022	EX-3.1	Amendment No. 1 to Amended and Restated Bylaws of Indaptus Therapeutics, Inc., dated as of July 20, 2022 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on July 20, 2022) Exhibit 3.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF INDAPTUS THERAPEUTICS, INC. This Amendment No. 1 (this ?Amendment?) to the Amended and Restated Bylaws of Indaptus Therapeutics, Inc., a Delaware corporation, dated July 23, 2021 (the ?Bylaws?), is made as of July 20, 2022 in accordance with adopted in accordance with Article 9 of the Bylaws. Capitalized terms used herein and not otherw
July 8, 2022	SC 13G/A	INDP / Indaptus Therapeutics, Inc. / Anderson Glen R. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Indaptus Therapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 45339J 105 (CUSIP Number) Glen R. Anderson Anderson Family Trust 101 South 200 East Suite 700 Salt Lake City, Utah 84111 +1.6
June 1, 2022	EX-4.2	Form of Subordinated Indenture Exhibit 4.2 INDAPTUS THERAPEUTICS, INC. TO [], as Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY THE GUARANTORS NAMED HEREIN INDENTURE Dated as of [], 20[] SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page Article One Definitions and Other Provisions of General Application 1 Section 101 Definitions 1 Section 102 Compliance Certificates and Opinions 11 Section 103 Form of Documents Delivere
June 1, 2022	EX-1.2	At the Market Offering Agreement by and between Indaptus Therapeutics, Inc. and H.C. Wainwright & Co., LLC, dated June 1, 2022 (incorporated by reference to Exhibit 1.2 of the Company’s Registration Statement on Form S-3 as filed on June 1, 2022). EX-1.2 2 ex1-2.htm Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT June 1, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Indaptus Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that fol
June 1, 2022	EX-FILING FEES	Filing Fee Exhibit Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Indaptus Therapeutics, Inc.
June 1, 2022	S-3	As filed with the Securities and Exchange Commission on June 1, 2022 As filed with the Securities and Exchange Commission on June 1, 2022 Registration No.
June 1, 2022	EX-4.1	Form of Senior Indenture Exhibit 4.1 INDAPTUS THERAPEUTICS, INC. TO [], as Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY THE GUARANTORS NAMED HEREIN INDENTURE Dated as of [], 20[] SENIOR DEBT SECURITIES TABLE OF CONTENTS Page Article One Definitions and Other Provisions of General Application 1 Section 101 Definitions 1 Section 102 Compliance Certificates and Opinions 10 Section 103 Form of Documents Delivered to T
June 1, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 1, 2022 INDAPTUS THERAPEUTICS, INC.
May 27, 2022	AW	Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 May 27, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-3 Post-Effective Amendment No. 1 dated August 16, 2021 and filed on August 16, 2021 and Post-Effective Amendment No. 1 dated A
May 19, 2022	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2022 INDAPTUS THERAPEUTICS, INC.
May 19, 2022	EX-99.1	Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors Exhibit 99.1 Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors NEW YORK (May 19, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Company?), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company?s Investigational New Drug (IND) application for a
May 12, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2022 INDAPTUS THERAPEUTICS, INC.
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indaptus T
May 12, 2022	EX-99.1	Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of So Exhibit 99.1 Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022 NEW YORK (May 12, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Company?), tod
March 25, 2022	AW	Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 AW 1 formaw.htm Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York, NY 10019 March 25, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Indaptus Therapeutics, Inc. Registration Statement on Form S-1 Post-Effective Amendment No. 1 File No. 333-230016 Ladies and Gentlemen: Pursuant to Rule 477 under the Se
March 22, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Indaptus Therapeutics, Inc.
March 22, 2022	EX-24.2	Power of Attorney for Mark J. Gilbert, M.D. Exhibit 24.2 POWER OF ATTORNEY March 22, 2022 The undersigned director of Indaptus Therapeutics, Inc. hereby constitutes and appoints Jeffrey A. Meckler and Nir Sassi, and each of them, with full power to act without the other, as such person?s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, i
March 22, 2022	POS AM	As filed with the Securities and Exchange Commission on March 22, 2022 As filed with the Securities and Exchange Commission on March 22, 2022 Registration No.
March 21, 2022	EX-21.1	List of Subsidiaries (incorporated herein by reference to Exhibit 21.1 to the Company’s Annual Report on Form 10-K filed with the SEC on March 13, 2024) Exhibit 21.1 List of Subsidiaries of Indaptus Therapeutics, Inc.: Name Jurisdiction of Incorporation/Formation Intec Pharma Ltd. Israel Decoy Biosystems, Inc. Delaware
March 21, 2022	EX-24.2	Power of Attorney for Mark J. Gilbert, M.D. Exhibit 24.2 POWER OF ATTORNEY March 21, 2022 The undersigned director of Indaptus Therapeutics, Inc. hereby constitutes and appoints Jeffrey A. Meckler and Nir Sassi, and each of them, with full power to act without the other, as such person?s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, i
March 21, 2022	POS AM	As filed with the Securities and Exchange Commission on March 21, 2022 As filed with the Securities and Exchange Commission on March 21, 2022 Registration No.
March 21, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 ex107.htm Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Indaptus Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offe
March 21, 2022	EX-10.6	Employment Agreement between Nir Sassi and Indaptus Therapeutics, Inc., effective as of January 1, 2022 (incorporated herein by reference to Exhibit 10.6 of the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2022) Exhibit 10.6 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), effective as of January 1, 2022 (the ?Effective Date?), is between Intec Pharma Ltd. an Israeli company number 51-3022780 (the ?Company?), the wholly-owned subsidiary of Indaptus Therapeutics, Inc. (the ?Indaptus?) and Nir Sassi, ID [*] whose address is [*] (the ?Executive?). WITNESSETH WHEREAS, the Company desires
March 21, 2022	EX-4.1	Description of Securities Registered under Section 12 (incorporated herein by reference to Exhibit 4.1 of the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2021) Exhibit 4.1 DESCRIPTION OF SECURITIES General The following description of our capital stock is a summary. This summary is subject to the DGCL and the complete text of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws. Our authorized capital stock consists of shares made up of 200,000,000 shares of common stock, par value $0.01 per share and 5,000,000 shares of
March 21, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 21, 2022 INDAPTUS THERAPEUTICS, INC.
March 21, 2022	EX-99.1	Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update NEW YORK (March 21, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Company?), today announces financial results for the fourth quarter and year ended December 31, 2021 and provides a corporate update. ?We enter 2022 excited about the future for Indaptu
March 21, 2022	EX-10.7	Employment Agreement with Boyan Litchev and Indaptus Therapeutics, Inc., effective as of January 1, 2022 (incorporated herein by reference to Exhibit 10.7 to Indaptus’ Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 21, 2022) Exhibit 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), effective as of January 31, 2021 (the ?Effective Date?), is between Indaptus Therapeutics, Inc. (the ?Company?) and Boyan Litchev (the ?Executive?). WITNESSETH WHEREAS, the Company desires to employ the Executive as its Chief Medical Officer, and the Executive desires to accept such employment, on the terms and conditi
March 21, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37521 INDAPTUS THERAP
February 11, 2022	SC 13G/A	INDP / Indaptus Therapeutics, Inc. / INTRACOASTAL CAPITAL, LLC - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea155267-13ga2intraindaptus.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Indaptus Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45339J105 (CUSIP Number) December 31, 2021 (Date of Event Which
February 1, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2022 INDAPTUS THERAPEUTICS, INC.
January 3, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 3, 2022 INDAPTUS THERAPEUTICS, INC.
January 3, 2022	EX-99.1	Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer Seasoned Drug Developer Brings More Than Twenty Years of Medical Leadership and Clinical Oncology Experience On Track to Initiate Phase 1 Study of Decoy20 in Exhibit 99.1 Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer Seasoned Drug Developer Brings More Than Twenty Years of Medical Leadership and Clinical Oncology Experience On Track to Initiate Phase 1 Study of Decoy20 in 2022 NEW YORK (January 3, 2022) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (?Indaptus? or the ?Company?), today announces the appointme
December 2, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 29, 2021 INDAPTUS THERAPEUTICS, INC.
November 30, 2021	POS AM	Power of Attorney As filed with the Securities and Exchange Commission on November 30, 2021 Registration No.
November 17, 2021	SC 13D/A	GAN / Gan Ltd / Anderson Glen R. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Indaptus Therapeutics, Inc. (Name of Issuer) Ordinary Shares, Par Value $0.01 Per Share (Title of Class of Securities) 45339J 105 (CUSIP Number) Glen R. Anderson Anderson Family Trust 3274 Ross Road Palo Alto, CA 94303 +1.650.493.7500 (Name, Address and
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 Indapt
November 15, 2021	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2021 INDAPTUS THERAPEUTICS, INC.

INDP / Indaptus Therapeutics, Inc. - SEC-arkivering, Årsberetning, Fuldmagtserklæring

Grundlæggende statistik

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?